Pharma major Dr Reddy’s Laboratories Ltd has launched Bupropion hydrochloride extended-release tablets, a therapeutically equivalent generic version of Zyban (Bupropion Hydrochloride) extended-release tablets in the US market.
Zyban is a trademark of the GSK group of companies. The Zyban brand and generic had U.S. sales of approximately $5.4 million for the most recent twelve months ending in June 2019 according to IQVIA Health.
Dr Reddy’s Bupropion hydrochloride extended-release tablets, USP (SR) are available as 150 mg dosage strength in bottle count sizes of 60, the Hyderabad-based company said in a release.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.